GDP Pharma: Good Distribution Practice for Medicines

GDP Pharma means Good Distribution Practice for medicinal products, a framework for maintaining their quality and integrity during wholesale distribution. The PIC/S PE 011-1 Introduction connects that objective to control of the distribution chain. This article focuses on medicinal-product distribution: how to organise the activities, responsibilities and evidence around that quality objective.

The objective extends beyond physical delivery. The PIC/S PE 011-1 Introduction also identifies preventing falsified medicines from entering the legal supply chain as a purpose of its guidance. GDP therefore concerns the integrity of the chain, not simply whether a shipment reaches its destination.

A useful way to read and apply the topics in this article is the following organisational sequence—not a prescribed regulatory sequence:

1. Identify the applicable framework and the distribution activity being assessed; use the dedicated EU GDP reference for the European framework.
2. Assign responsibilities so that each activity and decision has a clear owner.
3. Organise controls around distribution operations, from receipt and storage through dispatch and transportation.
4. Connect evidence to decisions: make it possible to follow what happened, who assessed it and what action followed. For exception handling, see GDP deviation management.

Choose a GDP reference by jurisdiction, product and activity—not by the acronym alone. A useful applicability assessment separates the guide used to design distribution controls from the local legal requirements governing the business.

The PIC/S PE 011-1 Introduction identifies the EU Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01) as its basis, but states that EU-specific references were removed. The adaptation is therefore not interchangeable with the EU text. Use the dedicated EU GDP reference for the EU-specific discussion.

The legal-status boundary is explicit: the PIC/S Introduction says PE 011-1 was adopted as guidance and leaves each participating authority to decide whether it becomes a legally binding standard.

WHO TRS 1025 Annex 7.pdf) addresses good storage and distribution practices for medical products. Its title should not substitute for a product-specific applicability check.

Use the following as a suggested screening structure, not a statement of national legal obligations.

The PIC/S Aide-Memoire, section 5.1, identifies items to investigate during GDP inspections of manufacturers and wholesale distributors. Use its inspection questions to structure review, not as a separate universal law.

For devices, supplements, food or chemicals, conduct separate applicability checks rather than automatically extending pharmaceutical GDP. Record the selected framework, local legal basis, product scope and activities covered so the choice can be reviewed when operations change.

These terms answer different operational questions. The comparison below distinguishes control purposes; it is not a set of legal definitions or serialization obligations.

The basic difference is where in the product's life each framework applies. The WHO glossary in TRS 1025 Annex 7.pdf) defines good manufacturing practices (GMP) as "That part of quality assurance that ensures that pharmaceutical products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the marketing authorization." It defines production as "All operations involved in the preparation of a medical product, from receipt of materials through processing, packaging and repackaging, labelling and relabelling, to completion of the finished product."

Distribution, in the same glossary, is "The procuring, purchasing, holding, storing, selling, supplying, importing, exporting or movement of medical products, with the exception of dispensing or providing medical products directly to a patient or his or her agent." In plain terms, GMP is about making the finished product right; GDP is about keeping that quality, identity and integrity intact once the product leaves manufacture and moves through wholesalers, warehouses and carriers. A manufacturer that also stores and ships its own finished goods therefore works under both sets of expectations, with a handover point that its own procedures should define clearly.

The PIC/S Introduction states that importation may fall under GMP in some participating-authority territories. That is a specific import boundary, not a universal classification of distribution activities.

Temperature evidence and identifier-based traceability support the broader quality system; neither replaces it. For role terminology, use the separate Qualified Person in pharma reference; distribution Responsible Person duties belong in the quality-system discussion.

The PIC/S Introduction defines wholesale distribution by activity: procuring, holding, supplying, importing or exporting medicinal products. Supplying medicinal products to the public is outside that definition. Start the scope assessment with what the business does, rather than its commercial description.

PIC/S PE 011-1, section 5.1 states that medicinal products distributed by a wholesaler must be appropriately authorised by national authorities for the intended market. This is a statement within the guide, not a separate national statute. For the European framework, see EU GDP.

Include both suppliers and customers in the counterparty boundary: section 2.3.5(vi) calls for ensuring that both are approved.

Use a scope register before expansion

A suggested scope register contains activity, product category, market, location, counterparty and outsourced service. These are practical organising fields, not prescribed regulatory field names.

When adding a product or opening a distribution route, use the register to identify which applicability and approval checks need revisiting. For example, a proposed route can be recorded against its destination market, receiving customer, dispatch location and contracted carrier. Review the changed entries together so that a familiar product does not obscure a new counterparty or service.

Does GDP apply when a manufacturer distributes its own products?

Yes. The PIC/S Introduction states that manufacturers performing distribution activities with their own products must comply with GDP.

GDP accountability starts with senior management. WHO Annex 7, section 5.2.pdf), assigns management ultimate responsibility for establishing, resourcing, implementing and maintaining an effective quality system. This is a guidance expectation: the objective is a functioning system, not simply a collection of approved procedures.

Connect procedures to people

WHO Annex 7, section 5.3.pdf), connects written operational procedures with responsibilities specified in job descriptions. The same section includes quality risk management and systems for managing changes, deviations and corrective and preventive actions (CAPAs). These belong within the distributor’s quality management system, rather than being treated as unrelated administrative processes.

As a practical implementation approach, review each distribution procedure alongside the relevant job descriptions. Ask who performs the work, who assesses a departure from the procedure and who owns any resulting action. Use the answers to expose gaps between documented operations and assigned responsibilities. The detailed investigation workflow belongs in GDP deviation management.

Give the Responsible Person a defined focus

PIC/S PE 011-1, section 2.3.5(ii), identifies management of authorised activities and the accuracy and quality of records as responsibilities of the designated Responsible Person. This gives the role an operational and documentary focus: what the distributor does and the quality of the records supporting that work.

Maintain training and document delegation

Under the PIC/S guidance, section 2.3.5(iii) assigns the Responsible Person responsibility for ensuring that initial and continuous training programmes are implemented and maintained. Training is therefore not limited to induction. Separately, section 2.3.5(ix) calls for appropriate records of delegated duties.

A useful implementation check is to compare the training programme, assigned jobs and delegation records for the same activity. Do they describe a coherent allocation of work? This is a practical review method, not a prescribed document format. Its purpose is to make gaps in coverage visible before they affect distribution operations.

Start with the product, not a standard warehouse temperature band. PIC/S PE 011-1, section 5.1 states that wholesale distribution is performed according to the information on the outer packaging. That is the anchor for handling conditions; this section assigns neither a default temperature range nor a generic permitted excursion.

For premises, PIC/S PE 011-1, section 3.2.1 recommends design or adaptation that maintains the required storage conditions. The inspection perspective also includes security: the PIC/S Aide-Memoire, Security asks whether access to premises and storage areas is appropriately controlled.

At receipt, the PIC/S Aide-Memoire, Receipt of Medicinal Products asks whether checks for products with special storage requirements establish that correct storage conditions were maintained during transportation. This is an inspection question about the journey, not merely the receiving area.

Illustrative evidence plan

The following study-design distinctions are practical planning aids, not prescribed regulatory protocols. They assign no mandatory sensor count, seasonal schedule or acceptance limit.

Worked case: missing transport observations

Assume transport-temperature observations are unavailable from 09:10 to 09:40 on the same day, using the same clock basis. The evidence gap is 30 minutes: 09:40 minus 09:10. That duration alone establishes neither the temperature experienced nor an allowable exposure.

Investigate whether the gap arose during measurement, transfer or retrieval; seek the original device record and any independent observations covering that interval. Record what remains unknown rather than treating missing readings as acceptable conditions. Use cold-chain deviation assessment for excursion-specific reasoning.

PIC/S PE 011-1, section 5.1 says key distribution operations should be fully described in appropriate quality-system documentation. For practical record design, distinguish the procedure describing an operation from the records showing what happened, which evidence was reviewed and who made the resulting decision.

The following inventory is a suggested organisation of distributor evidence, not a mandatory GDP form. Its categories and field names are design choices; they do not establish mandatory fields, retention periods or document formats.

These are concrete inspection materials: the PIC/S Aide-Memoire, Receipt of Medicinal Products, asks whether goods-receipt records, transport-temperature records, and routine stock-check records with subsequent investigations are available.

Connect evidence without merging its meaning

In plain language, the links that matter are few. Each shipment names a sender and a receiver. Each shipment line names the product lot it carried, so one lot can be followed across several shipments. Temperature and condition records attach to the shipment they describe. Any complaint, return or investigation attaches to the shipment and lot it concerns, and draws on the condition records as evidence. Finally, each case closes with its own decision record.

Keeping those links explicit lets a reviewer move in either direction: from a lot to every customer that received it, or from a temperature alarm to the stock and decisions it affected. It also prevents a common shortcut, where a monitoring file quietly becomes the release decision because nobody recorded who assessed it.

Keep the product and lot identity separate from the shipment identity, because one lot can appear in several shipments. Hold stock status against the stock actually held at a location, rather than treating a temperature file as a status decision. Link each case to its evidence and to a separate decision record showing the outcome, who decided and when. This supports lot pedigree without confusing product identity, movement identity, observations and authorised judgement.

Preserve context in electronic records

As implementation choices, capture originating_record_id, retain the original value and correction_reason, and associate observed_at, time_zone and unit with each observation. Identify the authorised person making each decision rather than inferring approval from a completed upload. These data-integrity-by-design measures help a reviewer reconstruct the sequence from receipt through assessment without treating data capture as an automatic quality release. Choose record granularity so a reviewer can retrieve the evidence for the affected shipment, lot and stock holding without relying on filenames alone.

A useful distribution workflow connects each movement to its supporting records and stock status. The lifecycle below is a suggested operating model, not a universally prescribed sequence.

The PIC/S Aide-Memoire, Receipt of Medicinal Products asks whether the goods-receipt procedure includes checking against a purchase order. In practice, connect that comparison to the goods receipt note, so the recorded receipt can be traced to the expected delivery.

A separate inspection question under Receipt of Medicinal Products addresses procedures for handling non-conforming product at receipt. Under Storage, the aide-memoire asks whether stock rotation follows first-expiry-first-out; see expiry-driven FEFO for the operational method.

1. Approved parties: start with the supplier and intended customer linked to their approval records.
2. Receipt: compare the delivery with the purchase order and connect quantities, product identity and accompanying evidence to the receipt record.
3. Exception assessment: route non-conforming product, suspect goods or missing evidence separately rather than treating every receipt as immediately saleable. Keep unresolved stock unavailable for dispatch pending an authorised person's decision. Investigation belongs in the exceptions section and in GDP deviation management.
4. Storage: record location and status separately; use FEFO when selecting eligible stock.
5. Dispatch preparation: connect the selected stock and quantities to the order and dispatch documents.
6. Delivery evidence and review: link delivery records back to dispatch, reconcile quantities and route unresolved discrepancies for assessment.

Worked case 2: physical stock versus saleable stock

Assume no opening stock, receipt of 120 cartons, dispatch of 84 cartons and quarantine of 12 cartons, with no other movements. Assume all remaining cartons outside quarantine are saleable.

• Saleable quantity: 120 − 84 − 12 = 24 cartons.
• Physical stock: 120 − 84 = 36 cartons, comprising 24 saleable and 12 quarantined.

Quarantine changes availability, not physical quantity. The arithmetic does not establish any actual medicine's acceptability.

PIC/S GDP guidance establishes a common starting point: complaints, returns, suspected falsified medicinal products and recalls must be recorded and handled carefully under written procedures. It also calls for designated personnel to assess returned medicines before any approval for resale (PIC/S PE 011-1, section 6.1). Recording a return is therefore distinct from deciding whether it can be resold.

The designated Responsible Person’s responsibilities include deciding the final disposition of returned, rejected, recalled or falsified products and approving returns to saleable stock (sections 2.3.5(x)–(xi)). A software status change or quantity calculation is not a substitute for that authorised decision.

Connect the event to its outcome

A suggested exception record can connect the following information without imposing an additional procedural sequence:

• Initiating event: complaint, return, suspected falsification or recall; reporter, date and description.
• Affected stock: product, lot, quantity and unit, linked receipt, shipment and customer records.
• Immediate controls: recorded stock restrictions, locations and people responsible for maintaining them.
• Investigation: evidence reviewed, findings, unresolved questions and links to related events.
• Decision and follow-up: authorised decision-maker, rationale, quantities by disposition, actions, owners and completion evidence.

Use the detailed method in GDP deviation management for investigation and corrective-action reasoning rather than treating this record structure as the investigation itself.

Worked case 3: a partial-return disposition

Assume 40 cartons are returned. After assessment, 26 cartons have authorised approval for resale; 14 cartons remain on hold. The reconciliation is 26 + 14 = 40 cartons.

The arithmetic accounts for all cartons; it does not establish product acceptability. This example assumes the approval exists and sets no generic acceptance criteria for returned medicines.

For recalls, coordinating and promptly performing operations is also a designated Responsible Person responsibility (section 2.3.5(iv)). Keep that coordination accountable to a named person; use recall readiness for related preparation rather than interpreting “promptly” as a fixed elapsed-time allowance.

PIC/S PE 011-1, section 2.3.5(vii) assigns the designated Responsible Person responsibility for approving subcontracted activities that may affect GDP. This is a guidance responsibility, not merely a purchasing decision.

Initial provider approval and subsequent performance monitoring answer different questions. The PIC/S Aide-Memoire, section 2, Management of Outsourced Activities, asks both how a company initially approves a service provider and whether it has a system for monitoring and reviewing contract acceptors’ performance. An approval record therefore addresses only one of these inspection questions.

Consider this proposed, vendor-neutral record-exchange design: a warehouse sends dispatch data, a carrier supplies transport-condition evidence, and the quality record links both to a shipment. Applying data integrity by design, define how missing evidence, rejected imports and duplicate messages will be handled:

1. Preserve the original message or document reference and record the failure; do not silently overwrite it.
2. Reconcile the affected shipment and quantities against dispatch records, identifying missing evidence or duplicate entries.
3. Request correction from the originating provider and link the corrected submission to the original reference.
4. Record the recovery and have the responsible reviewer check the reconstructed evidence before relying on it.

This recovery sequence is an operational design example, not a prescribed PIC/S interface specification. Use GDP deviation management for the associated quality assessment rather than treating successful data import as resolution of the underlying issue.

PIC/S PE 011-1, section 2.3.5(viii) assigns the designated responsible person responsibility for ensuring self-inspections occur at appropriate regular intervals under a prearranged programme, with necessary corrective measures put in place.

Use these illustrative review tests—not a ranking of inspection findings—to check evidence connections.

How should change control be tested?

Ask whether changes followed appropriate change-control procedures, as prompted by PIC/S Aide-Memoire, section 1, Review of key changes since previous inspection.

What specialist training should reviewers examine?

PIC/S Aide-Memoire, section 3, Training asks whether specific training covers temperature-sensitive products and controlled drugs.

Implementation checklist

Use this practical checklist, not a compliance certification:

• Is scope clear?
• Are responsibilities assigned?
• Can a shipment be traced through its evidence?
• Do exceptions have recorded decisions?
• Are contracted activities reviewed?
• Do corrective actions have follow-up?
• Are management-review outcomes documented and communicated internally, as asked in PIC/S Aide-Memoire, section 2, Management Review and Monitoring?